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Background: Limited research has examined the association between physical activity, health-related fitness, and
disease outcomes in breast cancer survivors. Here, we present the rationale and design of the Alberta Moving
Beyond Breast Cancer (AMBER) Study, a prospective cohort study designed specifically to examine the role of
physical activity and health-related fitness in breast cancer survivorship from the time of diagnosis and for the
balance of life. The AMBER Study will examine the role of physical activity and health-related fitness in facilitating
treatment completion, alleviating treatment side effects, hastening recovery after treatments, improving long term
quality of life, and reducing the risks of disease recurrence, other chronic diseases, and premature death.
Methods/Design: The AMBER Study will enroll 1500 newly diagnosed, incident, stage I-IIIc breast cancer survivors
in Alberta, Canada over a 5 year period. Assessments will be made at baseline (within 90 days of surgery), 1 year,
and 3 years consisting of objective and self-reported measurements of physical activity, health-related fitness, blood
collection, lymphedema, patient-reported outcomes, and determinants of physical activity. A final assessment at
5 years will measure patient-reported data only. The cohort members will be followed for an additional 5 years for
disease outcomes.
Discussion: The AMBER cohort will answer key questions related to physical activity and health-related fitness in
breast cancer survivors including: (1) the independent and interactive associations of physical activity and
health-related fitness with disease outcomes (e.g., recurrence, breast cancer-specific mortality, overall survival),
treatment completion rates, symptoms and side effects (e.g., pain, lymphedema, fatigue, neuropathy), quality of life,
and psychosocial functioning (e.g., anxiety, depression, self-esteem, happiness), (2) the determinants of physical
activity and health-related fitness including demographic, medical, social cognitive, and environmental variables, (3)
the mediators of any observed associations between physical activity, health-related fitness, and health outcomes
including biological, functional, and psychosocial, and (4) the moderators of any observed associations including
demographic, medical, and biological/disease factors. Taken together, these data will provide a comprehensive
inquiry into the outcomes, determinants, mechanisms, and moderators of physical activity and health-related fitness
in breast cancer survivors.
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Breast cancer is a major public health burden in Canada
with 23,600 women expected to be diagnosed in 2011
and 5,100 expected to die from the disease [1]. Over
their lifetime, Canadian women have about a one-in-
nine chance of developing breast cancer and a 1 in 29
chance of dying from the disease [1]. Breast cancer
accounts for 28% of all cancers diagnosed in women and
14% of all cancer deaths in women [1]. Early detection
and improved treatments have resulted in a five-year
relative survival rate of 88% [1]. The high incidence rate
and excellent survival rate have resulted in a growing
population of breast cancer survivors. In 2007, there
were an estimated 153,000 breast cancer survivors in
Canada diagnosed within the past 10 years, comprising
40% of all female cancer survivors in Canada [1]. Given
only survivors up to 10 years post-diagnosis were included
in the estimate, it is likely that there are over 200,000
breast cancer survivors currently in Canada. Breast cancer
survivors are at increased risk for many acute, chronic, and
late effects of their disease and treatments including breast
cancer recurrence, second cancers, cardiac dysfunction,
weight gain, bone loss, lymphedema, arthralgias, cognitive
dysfunction, menopausal symptoms, fatigue, and psycho-
social distress [2].
Physical activity (PA) and health-related fitness (HRF)
are essential for the health of any population but they
appear to be particularly important for breast cancer
survivors. A growing body of literature has examined
the associations between PA and disease outcomes in
breast cancer survivors and the preliminary results are
promising [3]. These studies are limited, however, be-
cause few were originally designed as breast cancer sur-
vivor cohorts and none were designed with a primary
focus on PA and HRF [3]. Consequently, these cohort
studies have methodological limitations including a reli-
ance on self-report PA measures that do not assess life-
time PA and other important domains of PA (e.g.,
occupational), no objective assessments of PA or HRF,
no measure of sedentary behavior, limited investigation
of potential biomarkers, and unstandardized assessment
time points.
Here, we report the design and methods of the Alberta
Moving Beyond Breast Cancer (AMBER) Study. To the
best of our knowledge, the AMBER Study is the first
prospective cohort study designed specifically to exam-
ine the role of PA and HRF in breast cancer survivor-
ship. The AMBER Study will address several gaps in the
literature by including:
1) a comprehensive self-report measure of PA [4,5] that
assesses the type, frequency, intensity, and duration
of PA at work, at home, and for recreation and
transportation;2) a self-report assessment of sedentary behavior, which
is emerging as an important independent predictor
of disease outcomes including cancer [6];
3) objectively-determined PA and sedentary behavior
(i.e., accelerometers);
4) a comprehensive assessment of HRF components
including standardized and validated measures of
maximal cardiorespiratory fitness, musculoskeletal
fitness, and body composition;
5) a comprehensive assessment of upper extremity
range of motion, testing of sensorimotor function
including balance, and surveillance of arm volume
and symptoms for the early detection of
lymphedema,
6) an assessment of biomarkers purported to mediate
the possible associations between PA, HRF, and
breast cancer outcomes;
7) assessment of key PROs including quality of life,
fatigue, and psychosocial function using standardized
and validated measures; and
8) a theoretical model of human behavior to examine
the determinants of PA.
Consequently, the AMBER Study will provide the
most comprehensive inquiry into the role of PA and
HRF in breast cancer survivorship to date. In the follow-
ing sections, we describe the methods and design of the
AMBER Study and discuss the five main projects that
guided its initial development.
Methods
Study design
The AMBER study protocol was approved by the
Alberta Cancer Research Ethics Committee and all parti-
cipants are required to provide written informed con-
sent. The AMBER Study is a prospective cohort study of
newly diagnosed breast cancer survivors in Alberta,
Canada. Flow through the study is depicted in Figure 1.
Assessments will be made at baseline, and one, three,
and five years follow-up and include clinic-based and
patient-reported measures. The clinic-based measures
will be completed at baseline, one and three years
whereas the patient-reported measures will be com-
pleted at all time points. The baseline assessment will be
completed within three months of definitive breast can-
cer surgery. The baseline blood draw will be pre-surgical
whenever possible, however, a post-surgical blood draw
will be acceptable as long as it is prior to the start of any
adjuvant therapy. For all other baseline assessments, the
goal is to complete them prior to any adjuvant therapy,
however, women may complete them after the start of
adjuvant therapy as long as they are still within three
months of surgery and have received less than one
chemotherapy cycle or less than two weeks of radiation
Figure 1 Flow of participants through the AMBER cohort study.
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apy, the baseline blood sample will be drawn prior to the
start of chemotherapy whereas all other baseline mea-
sures will be completed before the second cycle of
chemotherapy. The one-year assessment is intended to
capture the short-term effects of treatments on the vari-
ous health outcomes. This approach was selected over a
post-treatment time point given the highly varied length
of breast cancer treatments (i.e., from months to years).
The three-year assessment is intended to capture the
early survivorship recovery period and reflect a more
stable estimate of the various measures. The five-year
assessment will provide a longer term follow-up of self-
reported PA, PA determinants, and patient-reported
outcomes. After five years, study participants will be fol-
lowed passively for vital status including progressions,
recurrences, and new primaries through regular linkages
with vital status data maintained by the Alberta Cancer
Registry (ACR)..
Study population
Eligibility for the AMBER Study includes: (1) histologically-
confirmed stage 1 (T1cN0M0) to stage IIIc breast cancer
[7], (2) no prior cancer diagnosis except non-melanoma
skin cancer, (3) females ≥ 18 years old, (4) completing the
revised Physical Activity Readiness Questionnaire for Every-
one (rPAR-Q+) [8] and the electronic Physical Activity
Readiness Medical Examination questionnaire (ePARmed-
X+) [8]; in order to complete health-related fitness testing,
(5) living in and around two large metropolitan centres,
Edmonton and Calgary (and surrounding areas), (6) ability
to provide written informed consent and complete ques-
tionnaires in English, and (7) not pregnant. We will include
stage 1 (T1cN0M0) to stage IIIc breast cancer survivors to
ensure that we achieve a broad sample of the breast cancer
survivorship community while ensuring an adequate num-
ber of recurrences in this cohort.
Recruitment
Breast cancer survivors in Alberta being evaluated at the
Cross Cancer Institute in Edmonton and the Tom Baker
Cancer Centre in Calgary will be recruited. These two
cities include two-thirds of all breast cancer cases in
Alberta. Alberta Health Services has developed a rapid
breast cancer ascertainment method in Calgary, in con-
junction with the Alberta Cancer Research Biorepository
(ACRB) that uses a population-based sampling approach
to identify all breast cancer cases prior to surgery. In
Calgary, all newly diagnosed women are contacted by
the ACRB to provide a pre-surgical blood and tumour
tissue sample. If consent is obtained, their blood and tis-
sue samples are stored for future research purposes. A
letter of invitation, information brochure, and consent
form will be e-mailed to the potential study participantsand a telephone follow-up is used to recruit into the
study. Those that are interested in the study are admi-
nistered the rPAR-Q + by telephone by our certified
exercise physiologists prior to fitness testing. In
Edmonton, breast cancer survivors are recruited from
the New Patient Breast Clinic at the Cross Cancer Insti-
tute. Prospective participants are provided with a letter
of invitation, information brochure, consent form and
rPAR-Q + and asked to return it when they attend the
clinic for testing.
Measures
Appointments are made with Edmonton participants to
come to the Cross Cancer Institute and Behavioral
Medicine Fitness Center at the University of Alberta,
and with Calgary participants to come to the Tom Baker
Cancer Center and the Human Performance Laboratory
at Faculty of Kinesiology at the University of Calgary.
The assessments will be scheduled for one or two clinic
visits depending on participant preference and logistical
issues. Single day clinic visits will be split into morning
and afternoon assessments to avoid undue fatigue. The
assessments will include 1) questionnaires, (e.g., baseline
demographic and health history as well as patient-
reported outcomes), (2) review of the rPAR-Q + and
completion of the ePARmed-X + form, (3) completion of
HRF testing including DXA scans, (4) lymphedema/
upper body function measurements, (5) blood draw, and
(6) training in the use of the accelerometer and activity
monitor logs to complete a week-long objective PA
measurements.
Health and lifestyle questionnaires
Baseline health
Baseline demographic and health characteristics of the
study participants will be measured by self-administered
questionnaire and will include demographic characteristics
(marital status, education, income, employment status, eth-
nicity), menopausal status, menstrual and reproductive his-
tory, exogenous hormone use history, personal health
history, medication history, vitamin and supplement his-
tory, family history of cancer, and smoking and alcohol
drinking histories.
Physical activity
Self-reported PA will be assessed by the self-administered
Past Year Total Physical Activity Questionnaire [5]. This
questionnaire has been used in over 30,000 participants in
the Alberta Cohort Study (Tomorrow ProjectW) [9] and
measures all types and parameters of activity over the past
12 months. For this questionnaire, the recorded activity is
converted into MET-hours/week/year of activity performed
using the Compendium of Physical Activities developed by
Ainsworth and colleagues [10].
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Self-reported sedentary behavior will be assessed by a
questionnaire that has been adapted from the Australian
Longitudinal Study on Women’s Health and has been
shown to have acceptable reliability and validity [11].
The questionnaire includes five items assessing time
spent sitting (hours and minutes) each day in the follow-
ing domains: a) while traveling to and from places, b)
while at work, c) while watching television, d) while
using a computer at home, and e) at leisure not includ-
ing watching television, on a weekday and a weekend
day.
Dietary habits
Usual dietary intake in the previous 12 months will be
assessed using the Canadian version of the US National
Cancer Institute’s Diet History Questionnaire [12] that has
recently been updated to reflect changes in food practices
and nutrient content of foods. Due to its cognitive-based
design, this questionnaire captures usual intake better than
other well-tested and validated questionnaires, such as the
Block and Willett food frequency questionnaires [13]. Diet
is an important potential confounder given that total
energy intake can affect energy balance (i.e., body compos-
ition) along with PA. Furthermore, dietary composition
could affect markers of inflammation and insulin resistance
[14], two biomechanisms of interest in our study, and
hence will be controlled for in the analysis.
Patient-reported outcomes
Health-Related Quality of life (HRQoL) will be assessed
by the SF-36 version 2 which is a widely used self-report
measure designed to assess perceived health and func-
tioning [15,16]. It contains eight subscales labeled Phys-
ical Functioning, Role-Physical; Bodily Pain; General
Health; Vitality; Social Functioning; Mental Health; and
Role-Emotional. A physical component summary and a
mental component summary are also generated. Scales
are comprised of different numbers of items and use a
variety of rating formats. Raw scores are converted to a
standard metric (0–100), with higher scores being indi-
cative of a better health state. The validity and reliability
of the SF-36 has been established in a number of clinical
populations, including cancer patients [17]. The stand-
ard four-week version of the SF-36 will be used.
Fatigue will be assessed using the Fatigue Scale (FS)
[18] from the FACT measurement system. The FS con-
tains 13 items that measure the impact of fatigue on
cancer survivors. On the FS, higher scores represent less
fatigue, or less severe symptoms. All FS items are rated
on a 5-point Likert scale ranging from 0 (not at all) to 4
(very much). The FS assessment is brief, easy to admin-
ister, and has suitable evidence of internal consistency,
test-retest reliability, and convergent and discriminantvalidity, and clinically important thresholds have been
derived [18,19].
Depression symptoms will be assessed using the Patient
Health Questionnaire – 9 (PHQ-9) [20]. The PHQ-9
scores each of the 9 DSM-IV criteria and ranges from
“0” (not at all) to “3” (nearly every day). Items are pre-
ceded by the statement “Over the last 2 weeks, how
often have you been bothered by any of the following
problems?” [20] Satisfaction with life will be assessed
using Diener’s Satisfaction With Life Scale (SWL) [21].
The SWLS is a short 5-item instrument designed to
measure global cognitive judgments of satisfaction with
one's life. Happiness will be measured using the Happi-
ness Measure (HM) [22]. The HM contains a question
asking for the amount of time spent happy, unhappy,
and neutral in the past week. Percentage of time spent
happy in the previous week will be estimated.
Determinants of physical activity
The social cognitive determinants of PA behavior will be
assessed by self-administered questionnaires using the The-
ory of Planned Behavior variables of attitude (affective and
instrumental), subjective norm (injunctive and descriptive),
perceived behavioral control (self-efficacy and perceived
control), intentions, and planning. These measurements
are in accordance with Ajzen’s suggestions [23] and have
been shown to be reliable and valid within cancer popula-
tions [24-26]. In addition, barriers to exercise will be
assessed, including disease/treatment-related, life-related
and motivation-related barriers. Environmental determi-
nants of PA behavior will include examination of the rela-
tionship between location (postal code), neighborhood
walkability, and access to fitness facilities.
Objective measurements of physical activity and
sedentary behavior
PA and sedentary time will be measured objectively in all
study participants using the new Actigraph GT3X+ (Acti-
graph, LLC, Pensacola, FL). This small and lightweight
device is a highly sensitive instrument that records acceler-
ation using a tri-axial accelerometer. These data are digi-
tized by a 12-bit A/D converter 30 times per second
(30 Hz), filtered to capture normal human movement (i.e.,
0.25 to 2.5 Hz), and saved as an activity count in user
defined intervals (epochs). Activity counts (ct) provide an
indication of the duration and intensity of bodily move-
ment. These data will be summarized using established data
reduction methods [27,28], artificial neural network algo-
rithms that predict activity type (e.g. household, locomo-
tion, sport) and intensity (metabolic equivalents [METs])
[29], as well as traditional scoring methods to estimate
activity duration (hrs/d) using activity count thresholds (i.e.,
sedentary, light, moderate-vigorous). Participants will be
instructed to wear the monitor on their right hip for seven
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bathing or swimming. Additionally, they will be asked to
record, in a daily log, the time they put on and took off the
monitor each day and the activities they did when they
were not wearing a monitor. The participants will be
instructed in the use of the accelerometers after their HRF
assessments and will return the monitor and the logbook
to the study coordinator. Study participants will be asked to
wear the accelerometers at baseline, 1, and 3 years.
Health-related fitness assessments
The HRF assessments will be performed by Canadian
Society for Exercise Physiology Certified Exercise Phy-
siologists (CSEP:CEPW) using the same testing equip-
ment in both centres and following a detailed testing
protocol. They will complete the assessments in the fol-
lowing order during a morning session: resting BP and
HR; body composition/anthropometry; [using dual x-ray
absorptiometry (DXA)]; musculoskeletal fitness and
cardio-respiratory fitness. Specific upper and lower body
(chest and leg press) muscular strength and endurance
will be tested in the afternoon after adequate recovery if
the participant chooses single day testing. Otherwise the
muscular strength and endurance testing may be per-
formed the following visit. Adequate recovery time and
nutrition/ hydration will be provided to ensure that
accumulated fatigue is minimized. On the morning of
the first visit, the DXA scan and lymphedema assess-
ments will be performed. The total HRF assessment time
will be approximately 2–2.5 hours per day for two day
testing and 6–6.5 hours total over the morning and
afternoon for single day testing.
Resting heart rate and blood pressure
Using standardized procedures [30], after 5 minutes of
quiet sitting, resting heart rate will be measured using a
heart rate monitor (Polar Electro, Finland) and resting
blood pressure will be measured on the non-surgical
arm using a sphygmomanometer (WelchAllynW) and
stethoscope (3M™ LittmannW).
Body composition/athropometry
Standing height (stadiometer, North Bend, WA) and body
mass (HealthoMeter, Bradford, MA) without shoes will be
measured. Waist circumference will be measured using
the National Institutes of Health (NIH) protocol and hip
circumference will be measured using the World Health
Organization (WHO) procedure with an anthropometric
tape measure (Gulick tape measure, Gilroy, CA). Waist to
hip ratio and body mass index (kg ×m-2) will be calculated
[30]. A DXA scan with a full body image will be taken to
assess overall percent body fat, total lean body mass, total
fat mass, and bone mineral density.Cardiorespiratory fitness
Submaximal heart rate, blood pressure, blood oxygen sat-
uration (SpO2, Vacumed, Venura CA), rating of perceived
exertion (Borg CR10 scale) [31], ventilatory threshold
(VT) and peak oxygen uptake (VO2 peak) will be deter-
mined during a modified Bruce [32] graded exercise test
on a treadmill. The modified Bruce treadmill protocol will
be used because of the nature of the participants (e.g.,
large age range, varied fitness levels). During each tread-
mill test, all expired air will be collected and analyzed with
a calibrated TrueOne metabolic measurement system
(ParVo Medics Inc, Sandy, UT.). VT will be determined
using the V-slope method of Wasserman [33] and VO2
peak will be determined as the highest oxygen uptake
achieved during the treadmill test to volitional exhaustion.
Recovery heart rate and systolic blood pressure will be
measured 1 and 5 minutes after the treadmill test ends.
Muscular strength will be assessed using multiple
repetition maximum (mRM) strength tests for chest
press and leg press to determine the maximum weight
an individual can lift approximately 8 – 10 times. The
protocol will follow the National Strength and Condi-
tioning Association guidelines [34]. The mRM will be
used to predict a 1RM using the formulae reported by
Mayhew et al. [35]. Combined grip strength (kg) of the
right and left hands will be measured using a JAMAR
hydraulic hand dynamometer (Lafayette Instruments,
ID). A sum will also be calculated from the best score of
2 trials recorded for each hand according to the CPA-
FLA protocol [30].
Muscular Endurance of the abdominals will be assessed
by a partial curl-up test and will be performed according
to a standardized protocol [30,36]. Upper body muscular
endurance will be assessed using the chest press exercise
device described previously at a relative load of 50% of
predicted 1RM. Lower body muscular endurance will be
done using leg press at 70% of predicted 1RM.
Flexibility will be assessed by a trunk forward flexion
sit-and-reach test using a Wells-Dillon flexometer
according to a standardized protocol [30].
Objective measurements of physical functioning
Lymphedema will be assessed both by self-report and by
clinical examination. Complications such as infection
and venous thrombophlebitis in the limb will be recorded
at the time of assessment. Arm volume will be measured
objectively using the Perometer (Juzo, Cuyahoga Falls,
USA). The Perometer is an optoelectric limb volumeter
that uses infrared technology to quantify limb volume. It is
a validated, reliable and sensitive method for quantifying
limb volume [37,38]. This instrument provides assessments
of the entire limb volume, the percentage difference be-
tween limbs, and allows for inter-limb comparison over
time.
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The measurement of shoulder range of motion will be
performed by using a universal goniometer according to
standardized procedures [39]. Active and passive shoulder
movements will be measured and include the measure-
ments of forward flexion, abduction, internal rotation,
external rotation and horizontal abduction movements.Arm function
Arm function will be assessed using the Disabilities of
the Arm, Shoulder and Hand scale (DASH) [40]. The
scale measures the effect of arm function on 30 different
daily activities. It also examines symptoms such as pain,
weakness and numbness, and the degree of disability
related to work and recreational activity. The scale is
scored from 0 to 100 with higher scores indicating
greater disability. This scale has been well documented
and shown to be reliable and valid.Peripheral neuropathy
Peripheral neuropathy will be assessed by self-report and
objective measures of sensorimotor function, strength
and balance testing.Blood data collection
The baseline blood draw will be done after an overnight fast
of at least eight hours. A 60 ml sample will be taken at
baseline and a 30 ml sample will be taken at 1 and 3 year
follow-ups. For this study, we will store 24 aliquots per per-
son for baseline blood draw (14 serum, 6 plasma, 2 buffy
coat and 2 red blood cells) and 16 aliquots per person for 1
and 3 year follow-up blood draw (8 serum, 5 plasma, 1
buffy coat and 2 red blood cells). A complete blood collec-
tion, processing, shipping and storage protocol has been
developed to ensure standardization of the procedures for
the bloods at the collection sites in Calgary (Calgary La-
boratory Services) and Edmonton (Cross Cancer Institute).
The aliquoted blood samples will be stored in our −86°C
freezers.Medical record abstraction
Health Record Technicians from the Alberta Cancer Regis-
try will use standardized forms and methods to abstract
the medical charts for all of the participants at regular
intervals during the cohort study. The form was previously
developed and tested for our past PA and breast cancer
cohort study that evolved from a population-based case–
control study that we conducted in Alberta [41]. Medical
variables to be abstracted will include pathologic and clin-
ical disease stage (TNM), type of surgery, and all treatment
and follow-up care including data on chemotherapy,radiation therapy, and hormone therapy. Pathology data
will include tumor size, grade, histology, estrogen receptor
status, human epidermal growth factor receptor 2 (HER2-
neu) status, type and results of computerized tomography
(CT) or positron emission tomography (PET) scans, status
of margins (with breast conserving surgery), and pathology
of lymph nodes (if surgically sampled).
Treatment completion rates will be estimated for chemo-
therapy and hormone therapy but not for radiation therapy
since few survivors fail to complete radiation therapy. For
chemotherapy completion rate, we will estimate the aver-
age relative dose intensity (RDI) received for the originally
planned regimen based on standard formulae as we have
done in a previous RCT [42]. For hormone therapy com-
pletion rate, it is not feasible to obtain an objective meas-
ure of treatment adherence. Consequently, participants will
be asked to report if they have stopped taking their pre-
scribed hormone therapy at any time before its intended
completion and the reasons for stopping their treatments.
Disease endpoints will be defined and assessed based
on the Standardized Definitions for Efficacy End Points
in Adjuvant Breast Cancer Trials (the STEEP system)
[43]. We selected recurrence-free interval (RFI) as our
primary disease endpoint because it consists of events
directly attributed to breast cancer including invasive ip-
silateral breast tumor recurrence, local/regional invasive
recurrence, distant recurrence, and death from breast
cancer. We will also examine other composite disease
endpoints as secondary endpoints including overall sur-
vival, invasive disease-free survival, distant disease-free
survival, distant relapse-free survival, breast cancer-free
interval, and distant recurrence-free interval. Finally, we
will examine the single disease endpoints of death from
breast cancer and death from non-breast cancer. These
endpoints will be abstracted by the health records tech-
nicians at the time of the medical chart reviews described
above.
Information on all deaths that occurred in the prov-
ince is provided by Vital Statistics Alberta (VSA) to the
ACR on a monthly basis with underlying cause of death
provided by Statistics Canada to VSA. There is an aver-
age three-month time lag between the actual death oc-
currence and reporting to the ACR. For cases that leave
the province after diagnosis, several mechanisms exist to
capture their deaths with reciprocal agreements between
other provinces and record linkages with the Canadian
Mortality Database that are undertaken with the ACR
data. These agreements and processes ensure that vital
status can be determined for over 95% of cases. For
cases who have left the province and who are not known
to be dead, the date of leaving Alberta will be used as
the censoring time. For the follow-up of this cohort,
yearly checks of the vital status of the breast cancer sur-
vivors will be conducted through linkages with the ACR.
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this source.
Sample size and power considerations
Although a cohort study such as this one has many
exposures, time points, and endpoints of interest, we
chose to power our study using cardiorespiratory fitness
at one-year follow-up as the primary exposure/time
point, and recurrence free interval (RFI) as the primary
endpoint because of the importance of these variables
but also because of the substantial power needed to de-
tect this association. By designing the study with ad-
equate power for this association, we ensured sufficient
power for all the other objectives that require substan-
tially less power. We designed the study to detect a 30%
risk reduction of RFI in survivors who are in the top
quartile of cardiorespiratory fitness, compared to those
who are in the lowest quartile (hazard ratio = 0.7). The
sample size was determined under the framework of
Cox proportional hazards (PH) models, adjusting for
known potential confounders such as age, BMI, tumor
stage, treatment, alcohol intake, diet, smoking and co-
morbidity. A statistical power of 80% and a two-sided α
= 0.05 were used. This setting requires 223 to 401 events
(PASS 2005); the exact number depends on how strong
the association is between cardiorespiratory fitness and
the confounders in the Cox PH model. A stronger asso-
ciation requires a larger number of events. The associ-
ation among variables is quantified by R2 of a multiple
linear regression model where cardiorespiratory fitness
is regressed onto the confounders. In the above calcula-
tion, we have considered a range of R2 between 0.1
(requiring 223 events) and 0.5 (requiring 401 events)
that we deemed realistic. The R2 can be reduced by
using cardiorespiratory fitness quartiles that are adjusted
for some of the major confounders such as age and
BMI, ensuring the R2 value of less or equal to 0.5. Thus,
our study is sufficiently powered for the primary object-
ive if we have more than 401 events.
The annual recurrence rate for localized invasive
breast cancer is estimated to be 2 ~ 3% [44]. For stage I
– IIIc patients combined, a first five-year recurrence rate
of 20% has been reported [45,46]. To attain the desired
number of events, we are using a stratified sampling de-
sign based on the projected breast cancer cases diag-
nosed in 2012–15 who will be treated in Edmonton or
Calgary. We plan to recruit a total of 1500 breast cancer
survivors from the two locations. Given the projected
numbers of survivors seen at two locations for each
stage, and, assuming an overall 50% consent rate for par-
ticipation, the recruitment will be completed within
5 years. This recruitment plan will provide a median of
about seven years of follow-up by the end of this study
in year 2022, and will yield a minimum of 460 events.Allowing for a 10% loss to follow-up, we expect to ob-
serve, at minimum, 414 events in this cohort.
Discussion
The primary focus of the AMBER Study will be to identify
the independent and interactive associations of PA and
HRF with disease outcomes (e.g., recurrence, breast cancer-
specific mortality, overall survival). Other important health
outcomes will include treatment completion rates, symp-
toms and side effects (e.g., pain, lymphedema, fatigue,
cognitive dysfunction), and PROs (e.g., QoL, anxiety, de-
pression, self-esteem, happiness). We will also be able to
examine the mediators and moderators of any observed
associations between PA, HRF, and health outcomes.
Finally, we will be able to identify the key determinants of
PA and HRF including demographic, medical, and social
cognitive variables, at various time points across the sur-
vivorship trajectory. Taken together, these data will provide
a detailed understanding of the unique benefits, risks, and
determinants of PA and HRF at multiple time points of sur-
vivorship so that intervention strategies can be developed
to help breast cancer survivors achieve and maintain
healthy levels of PA and HRF. The AMBER Study is
designed initially to address the following five major re-
search themes.
Physical activity, health-related fitness, and disease
outcomes
The primary aim of this project is to examine the associa-
tions between self-reported and objective PA (including
sedentary behavior), HRF (including body composition),
and disease outcomes in breast cancer survivors (including
recurrence-free interval, breast cancer mortality, and over-
all survival). These data will provide critical information on
the optimal type, volume, and pattern (i.e., how the volume
is achieved over a given week) of PA that may be most
strongly associated with disease outcomes in breast cancer
survivors. Moreover, while previous studies have used
self-report PA assessments, the use of accelerometers to
measure PA will provide an accurate (and gold-standard)
estimate of PA at multiple time points across the survivor-
ship trajectory. Further, no studies have examined associa-
tions between objectively-determined PA and disease
endpoints. Multivariable analyses will be able to determine
any independent associations of the PA and HRF variables
with disease outcomes that may identify one or more PA-
related exposures of primary importance. For example, two
research questions will be to determine whether: (a) cardi-
orespiratory fitness and muscular strength or other HRF
assessments are independently associated with disease out-
comes among breast cancer survivors, and (b) vigorous PA
and sedentary behavior are independently associated with
disease outcomes. A secondary aim is to examine potential
moderators (effect modifiers) of the associations between
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critical information on which subgroups of survivors may
benefit the most from engaging in PA and may also even
identify different optimal PA prescriptions for different sur-
vivor subgroups. The ultimate goal of this project is to pro-
vide insights regarding the relative importance of various
aspects of the PA prescription and the various HRF com-
ponents for breast cancer outcomes that will be directly
relevant for PA and sedentary behavior recommendations
for breast cancer survivors.
Physical activity, health-related fitness, and biologic
mechanisms
The primary aim of this project is to examine the mechan-
isms that may explain any associations between self-
reported and objective PA (including sedentary behavior),
HRF (including body composition), and disease outcomes
in breast cancer survivors (including recurrence-free inter-
val, breast cancer mortality, and overall survival). The exact
biologic mechanisms whereby PA and HRF may influence
breast cancer recurrence and survival have not yet been
delineated. More research has focused on the role of PA in
breast cancer incidence. One hypothesized biologic model
for postmenopausal breast cancer risk implicates adiposity,
sex hormones, insulin resistance and chronic inflammation
as mediators of PA [47]. This model is further supported
by recent results from exercise intervention trials that
demonstrated a direct impact of PA on sex hormones
[48,49] and adiposity levels [50], which are both convin-
cingly associated with postmenopausal breast cancer risk
in the epidemiologic literature [47]. The same model and
biologic rationale relating PA to postmenopausal breast
cancer risk [47] can be adapted to breast cancer recurrence
and survival since many of the same biomarkers have been
associated with PA in breast cancer survivors, and breast
cancer recurrence/survival, respectively. Adaptations to the
model include the addition of breast cancer therapies and
their potential influence on biomarkers [51,52] as well as
the addition of insulin-like growth factor 1 (IGF-1) and
IGF binding protein 3 (IGFBP-3). HRF (i.e., body compos-
ition, muscular strength, muscular endurance, cardiore-
spiratory fitness) can also be added to the model since
body composition is influenced by PA, changes in muscle
mass may affect insulin resistance, and in one recent
healthy cohort study, cardiorespiratory fitness was found
to decrease risk of breast cancer death through an un-
known mechanism [53].
Clearly, there is a lack of consistent information relat-
ing PA and breast cancer outcomes to our hypothesized
biomarkers. A better understanding of the underlying
biologic pathways involved in the association between
PA and breast cancer outcomes could be gained with a
sufficiently powered study using more accurate measures
of body fat, valid measures of PA, and careful control forpatient and tumor-related moderators of the effects of
PA on breast cancer outcome. Serial measurements of
our proposed biomarkers over time will be a novel attri-
bute of this study and will enable us to identify signifi-
cant time points for influencing breast cancer outcome
and the effect of biomarker level changes over time. This
understanding will add biologic plausibility to the associ-
ation between PA and breast cancer outcome, guide fu-
ture epidemiologic research, identify new targets for
interventions, and inform clinical recommendations for
improving survival after breast cancer diagnosis.
Physical activity, health-related fitness, and patient-
reported outcomes
The primary aim of this project is to examine the asso-
ciations between PA, HRF, and PROs across the breast
cancer continuum. Breast cancer survivors have an ele-
vated risk for poor QoL, anxiety, depression, fatigue, and
cognitive impairment both during treatment [54] and
throughout survivorship [55,56]. Some evidence suggests
that women surviving cancer may continue to demon-
strate poor function on various PROs for up to 10 years
after their initial diagnosis [57-59]. While preventing
declines in PROs after a breast cancer diagnosis is im-
portant, new research is suggesting that less decline in
QoL during adjuvant therapy for breast cancer may also
be associated with a reduced risk of breast cancer recur-
rence [60] (Sarenmalm et al., 2009).
Systematic reviews support the role of PA as a safe
and effective intervention to improve HRF and selected
PROs in breast cancer survivors, particularly during sur-
vivorship [61,62]. The most commonly studied PROs in
PA research are fatigue, QoL, physical functioning, de-
pression, and anxiety [62]. Systematic reviews provide
evidence that PA can improve patient-reported physical
functioning and anxiety during treatment, and QoL, fa-
tigue, depression, and anxiety during survivorship. In
particular, these studies suggest that particular QoL
domains, especially physical well-being, functional well-
being, and fatigue appear to be domains that are most
likely affected by PA. Indeed, some data suggest that
improvements in several PROs are dependent on
changes in HRF such as cardiorespiratory fitness [63,64].
Although over 50 randomized controlled trials (RCTs)
have examined the effects of PA on PROs in breast can-
cer survivors [62], few of these trials have had adequate
power for subgroup analysis, few have examined the op-
timal type of PA (e.g., aerobic, resistance) or intensity of
PA (e.g., light, moderate, vigorous activities), few have
examined the HRF components most relevant to PROs,
and few have examined the effects of PA or HRF on
PROs across the continuum of breast cancer survivor-
ship (e.g., treatment, early survivorship, later survivor-
ship). Little is known about other relevant PROs such as
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toms, and psychological well-being (e.g., happiness and
satisfaction with life). Further, to date there are no stud-
ies examining sedentary behavior (time spent sitting)
and associations with PROs among breast cancer survi-
vors. Information of this nature may facilitate further
understanding of how PA and sedentary behavior is
related to PROs during breast cancer survivorship. This
project will also examine important mediators and mod-
erators of the associations between PA, HRF, and PROs.
Physical activity, health-related fitness, and physical
functioning
This project will examine the relationship between PA,
HRF and the incidence, severity and natural progression
of lymphedema and upper limb morbidity (e.g., pain,
numbness, weakness and shoulder dysfunction) from
diagnosis through treatment and recovery from breast
cancer. Lymphedema is a chronic swelling of the limb on
the surgical side that may present immediately or many
years after treatment [65,66]. More recent estimates sug-
gest an incidence rate of around 20%, with higher rates
found in studies with longer follow-up [67,68]. Lymphe-
dema is a known consequence of surgical and radiothera-
peutic techniques and is known to have deleterious effects
on QoL [69]. Among systemic factors, obesity has been
associated with increased lymphedema risk [70]. While
PA has been traditionally viewed as a possible risk factor,
PA has not been associated with lymphedema in prospect-
ive research and more recent evidence suggests a possible
protective effect of PA [71].
Upper limb morbidity occurs frequently following
treatment for breast cancer [71,72] and recent evidence
suggests symptoms such as pain and shoulder dysfunc-
tion are more prevalent than lymphedema [72]. Al-
though upper limb morbidity is reduced with newer
techniques such as Sentinel Lymph Node Biopsy, studies
have shown that a majority of breast cancer survivors
have at least one upper limb symptom (e.g., numbness,
pain, weakness, swelling, stiffness) in the long term [67].
Peripheral neuropathy is a condition that results from
damage to or dysfunction of the peripheral nerves [73]. In
breast cancer survivors this damage may occur from ad-
ministration of a neurotoxic chemotherapeutic agent [73].
Sensory symptoms associated with chemotherapy induced
peripheral neuropathy include numbness, tingling and
pain that presents in the distal aspects of the upper and
lower extremities, often described as a stocking/glove dis-
tribution [74]. Motor symptoms associated with the con-
dition may include upper and lower limb weakness,
impaired proprioception and balance. Functional impair-
ments may result in difficulty performing fine motor tasks,
walking and increase the risk falling [74]. Thus, breast
cancer survivors experiencing treatment related effectssuch as lymphedema, upper limb morbidity and periph-
eral neuropathy, may have unique challenges that impact
their PA, HRF, and PROs.
Determinants of physical activity and health-related
fitness
The aim of this study is to develop a comprehensive
understanding of the determinants of PA in breast cancer
survivors across the survivorship continuum. A social eco-
logical approach and a theoretical framework [i.e., Theory
of Planned Behavior (TPB)] will be used to identify key
determinants of both the adoption and maintenance of
PA across the continuum of breast cancer survivorship
including social cognitive, demographic, personal, bio-
logical, medical, and environmental factors. The social
ecological approach provides a broad framework to exam-
ine the multiple effects and interrelatedness of these fac-
tors at all levels of influence (i.e., individual, interpersonal,
organizational, community, and society). Moreover, the
TPB is one of the most widely tested theoretical frame-
works within the PA and cancer literature.
More research is necessary to determine the specific
relationship between these demographic variables and
aspects of PA, including specifically the type, frequency,
duration and intensity, as well as the timing of PA across
the breast cancer continuum. Less is known about the
role of medical factors as determinants, although PA
participation consistently decreases with advanced breast
cancer and during treatments. No research to date has
specifically examined the role of biological factors as
determinants of PA behavior during and after treatment.
Therefore, examining biomarkers as PA determinants
may provide a unique insight into the role of cancer-
related biology as a determinant of PA.
Given the scarcity of literature on the myriad of deter-
minants of PA for breast cancer survivors, the proposed
prospective cohort study will generate new knowledge
and be instrumental in formulating eventual clinical and
community-based programming for breast cancer survi-
vors. We will more clearly elucidate the complex inter-
play between a range of determinants and PA adoption
and maintenance. Ultimately, the determinants project
will enable us to achieve more effectively targeted inter-
ventions that help breast cancer survivors achieve
healthy levels of PA and HRF.
In summary, the AMBER Study will establish a cohort
in which we will conduct five initial studies that address
the outcomes, determinants, mechanisms, and modera-
tors of PA and HRF in breast cancer survivors. The
AMBER Study will answer wide-ranging questions
related to PA and HRF in breast cancer survivors. The
result will be a unique data source containing data from
objective and gold-standard measures that has not previ-
ously been created. This study will provide insight into a
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questions will arise for which the AMBER Study could
provide timely answers. The ultimate goal of this re-
search is to identify how PA and HRF can be used to in-
form clinical and public health recommendations for
improving outcomes after breast cancer.
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